Browse studies

Find your next paid study

700 recruiting studies matching your filters

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the…

Small Cell Lung Cancer Extensive Stage

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07227597

Phase 1

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

Estimated

~$10 – $8,750

Phase 1

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-…

Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+8 more

Estimated

~$10 – $8,750

Radiopharm Theranostics, LtdNCT07189871

Phase 2

Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and m…

Lung CancerLung Cancer Stage IILung Cancer Stage III

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04991025

Phase 1

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that …

Recurrent Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer+6 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07509034

Phase 3

A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistan…

Patients With Non-Small Cell Lung Cancer

Estimated

~$10 – $8,750

OSE ImmunotherapeuticsNCT06472245

Phase 2

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolli…

Advanced Solid TumorMelanomaHead and Neck Cancer+11 more

Estimated

~$10 – $7,500

Daiichi SankyoNCT06172478

Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies

Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and p…

Thoracic CancersMalignant Pleural Mesotheliomas NOSLung Cancer NOS+3 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00242723

Prospective Multiomic Analysis in Small-Cell Lung Cancer to Inform Therapeutic Vulnerabilities and Predict Clinical Outcomes: Deep Phenotyping of Relapsed SCLC Cohort

This is an observational study to collects blood samples and tumor tissue from adults with relapsed small-cell lung cancer (SCLC) receiving standard of care co…

Small Cell Cancer Of The LungSmall Cell Lung Cancer ( SCLC )Lung Cancer+1 more

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT07795411

Phase 3

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-ris…

Non-small Cell Lung Cancer

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07513376

Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gath…

Non-Small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT02146170

Observational

Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - LungSMART UH3 Clinical Trial

The long-term goal of Lung Sequential Multiple Assignment Randomized Trial (LungSMART) Utah is to increase the reach of Low-Dose Computed Tomography (LDCT) scr…

Lung Cancer

Estimated

~$10 – $6,250

University of UtahNCT07599943